Suggested remit: To appraise the clinical and cost effectiveness of pegcetacoplan within its marketing authorisation for treating primary complement 3 (C3) glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in people 12 years and over.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6489
Provisional Schedule
- Committee meeting:
- 04 February 2026
- Expected publication:
- 18 June 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Swedish Orphan Biovitrum (pegcetacoplan)
- Others
- National Renal Complement Therapeutics Centre
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Kidney Care UK
- Kidney Research UK
- MPGN/DDD Support Group
- National Kidney Federation
- Polycystic Kidney Disease Charity
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Renal Industries
- Association of Renal Technologists
- British Association of Paediatric Nephrology
- British Association of Urological Nurses
- British Association of Urological Surgeons
- British Geriatrics Society
- British Society for Immunology
- Neonatal and Paediatric Pharmacists Group
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for DGH Nephrologists
- UK Clinical Pharmacy Association
- UK Kidney Association
- UK Renal Pharmacy Group
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Alexion Pharma (eculizumab)
- Amgen (eculizumab)
- Novartis (iptacopan)
- Roche (mycophenolate mofetil)
- Rosemont Pharmaceuticals (mycophenolate mofetil)
- Samsung Bioepis (eculizumab)
- Teva Pharma (mycophenolate mofetil)
- Tillomed Laboratories (mycophenolate mofetil)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Association of Renal Industries
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Kidney and Transplant Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
- Society for Research in Rehabilitation
- Wellcome Trust
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2025 | Invitation to participate |
| 14 April 2025 - 16 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6489 |
| 16 April 2025 | Referral |
| 16 April 2025 | Referral |
| 14 April 2025 | In progress. Scoping commenced. |
| 12 December 2024 | Referral |
| 08 October 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 08 October 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual